STUDresearch · Peptide
Vilon
Also known as
KE peptide · Lys-Glu · L-Lys-L-Glu · lysylglutamic acid · lysyl glutamate · thymus bioregulator Vilon · Vilon® (research / originator trade discussion) · cytogen KE · synthetic thymic dipeptide Lys-Glu
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Mixed
Oral / SubQ / intranasal
Longevity & bioregulators
Mixed-systemic — short thymus-addressed dipeptide framed for whole-body immune, chromatin, and geroprotective effects, not local soft-tissue repair.
What people say
Vilon is the synthetic KE dipeptide associated with thymus-bioregulator research. It is different from Thymogen, Thymalin extract and Thymosin Alpha-1; most mechanistic evidence comes from one research lineage rather than modern outcome trials.
Doses people talk about
These are reported amounts, not a progression. Course totals are not per-dose amounts, and oral capsule content is often unspecified.
How it may feel
No isolated Vilon feel is dependable. One poster reported overnight change on intranasal Vilon plus VIP and many co-agents, then weaker and non-durable effects; another poster described shorter workout soreness without an amount or follow-up.
SubQ community band~100–500 mcg once daily
A common chart range; no Western dose-ranging trial establishes a therapeutic amount.
Short SubQ pulse chart~67–200 mcg once daily for 5 days
A community chart describes this five-day SubQ schedule; it is not a controlled human dose-ranging result.
Actual intranasal combination report250 mcg intranasal twice daily
The poster paired Vilon with 50 mcg intranasal VIP twice daily and many other agents; earlier narrative also mentioned 1 mg/day Vilon, so the two statements are not merged.
Half-life & effect duration
- Half-life in the body
- KE / VilonNo settled estimate
- Felt duration people report
- One Vilon + VIP accountRapid overnight improvement, then weaker response, relapse and no durable effect
- Other accountShorter workout soreness
Cycles people discuss
Community charts emphasize 5–10-day pulses, with some 10–20-day courses and months off. Monthly mini-pulses and organ rotations are reported calendar traditions, not independently validated exposure schedules.
Timing
Oral charts usually pair morning capsules with meals; SubQ charts often use a consistent morning time on dosing days. Once-daily use is common and split dosing uncommon in those charts; empty-stomach SubQ rules in some guides are not backed by controlled timing trials.
Stacks
Vilon is discussed with Epitalon, Thymalin and rotating organ bioregulators. The actual long-COVID account paired it with VIP plus modafinil, propranolol, T3, other peptides, LDN, amitriptyline, melatonin, testosterone and helminths, preventing attribution.
Watch for
Coagulation flag: The 2007 diabetes/age cohort reported coagulation-hemostasis parameter shifts — anyone on anticoagulants/antiplatelets, with clotting disorders, or facing surgery should treat that as a specific discussion point, not a footnote.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No independent modern human elimination half-life was established for KE/Vilon.
The reviewed paper describes KE identity and cell, animal and ex-vivo findings but does not provide a product-specific human ADME curve.
Originator-line narrative review; oral, intranasal and injected products differ, and rapid proteolysis cannot be converted into a numeric half-life without measurement.
- The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity (opens in a new tab)Full text, especially abstract and sections identifying KE as Vilon and describing immune-cell, chromatin and gene-expression findings; actual full text and references read. No human Vilon pharmacokinetic curve was reported.Narrative review authored by the originating research group, combining cell, animal, ex-vivo human and clinical-era evidence; not a Vilon ADME or modern outcome trial.
Felt duration people report
An overnight combination response, later relapse and a separate soreness report do not establish Vilon-only onset or duration.
The long-COVID poster initially described rapid improvement on Vilon plus VIP and many co-agents, then weaker response, relapse and no durable effect; a separate poster reported shorter workout soreness without dose detail.
Self-selected accounts, inconsistent regimen narration, extensive co-exposures and no blinded or objective Vilon comparison.
- Great results with VIP/Vilon combo for ME/CFS/LongCovid (opens in a new tab)Read the OP, regimen details and same-author updates through 2024: intranasal VIP 50 mcg twice daily and Vilon 250 mcg twice daily in one regimen description, earlier 1 mg/day Vilon narrative, initial overnight improvement, later slump/relapse, weaker effects and eventual statement that benefit was not durable; extensive medication, hormone, peptide and lifestyle co-exposures recorded.Single unverified self-report with internally changing amounts and a very large co-intervention stack; cannot isolate Vilon, VIP or disease fluctuation.
- Lesser Known, But Amazing Peptides — Vilon reply (opens in a new tab)TheMowiSchmowi reply reporting workout soreness shortened to at most about one day; read the surrounding follow-up asking for dose, which had no visible answer.One brief uncontrolled report with no amount, route, product verification, baseline tracking or same-author outcome follow-up.
What people say
- Immune resilience (community): Fewer lingering seasonal colds, steadier winter seasons, or “bounce-back” after illness claimed after short pulses — heavily confounded by stacks, sleep, and selection bias. forumanecdote
- Feel: Little-to-no acute “stim,” mood lift, or pump; claimed benefits are gradual resilience metrics over weeks–months, not day-one phenomenology. forumanecdote
- Stack role: Thymus/immune leg in multi-bioregulator rotations (classic pair with Epitalon / Epithalamin; sometimes Thymalin extract or other cytogens) rather than a solo hero compound. forum
- Vs Thymalin extract: Treated as the synthetic KE stand-in for one thymic-signal component — more chemically defined on paper, not automatically equivalent in multi-fraction clinical extract history. forumtrial
- Thymus / T-cell differentiation (preclinical): Cell and animal work reports increased thymocyte proliferative activity, wider cortical thymic architecture in injury models, and higher expression of differentiation markers such as CD5 and CD4 on thymic cells — framed as helper/cytotoxic lineage maturation, not acute antiviral therapy. animallab
- Cytokine balance (cell models): Activation of IL-2-related signaling in lymphocyte preparations alongside reduced inflammatory cytokine output in stimulated cultures (some writeups cite large fold-reductions) — dual “support response / dampen chronic inflammation” narrative common in bro-science summaries. lab
- Chromatin / gene expression (ex-vivo): Lymphocytes from older donors show deheterochromatinization / reactivation of facultative heterochromatin and nucleolar-organizer activity after KE exposure; originator gene-array talk includes multi-gene expression shifts (Vilon alone vs Vilon+Epitalon combination reported to move larger gene sets). labtrial
- Immunosenescence framing: Positioned against age-related thymic involution and naive T-cell decline rather than as a rescue drug for active immunodeficiency. forumtrial
- Lifespan / activity (rodent lineage): Chronic subcutaneous KE in female CBA mice from mid-life was associated in originator papers with higher physical activity/endurance and reduced spontaneous lung-adenoma burden; secondary blogs often quote large mean-lifespan percentages — cross-check primary abstracts, because head-to-head thymic-vs-pineal peptide papers sometimes attribute clearer mean-survival gains to the pineal tetrapeptide rather than Lys-Glu alone. animal
- Tumor models (rodent only): Inhibitory effects on spontaneous or induced tumor endpoints reported in mouse work — not a human oncology therapy and not a reason to self-treat cancer. animal
- Coagulation / diabetes cohort (human-era Russian data): Adv Gerontol 2007 cohort in patients of different ages with diabetes mellitus reported shifts in immune status and coagulation hemostasis (and secondary summaries mention insulin-requirement changes in elderly subjects) — small, non-Western-RCT dataset; clotting-parameter movement is a benefit signal and a caution flag. trial
- What it is not proven for: Diagnosed immunodeficiency, infection treatment, cancer, vaccine non-response, or any FDA-labeled indication — research/educational framing only. trial
Doses people talk about
- Injectable community standard (most-cited band): ~100–500 mcg subcutaneously once daily; 100 mcg often named as a common start. forum
- Lower pulse charts: ~67–200 mcg SC once daily for 5 consecutive days. The underlying chart is not a controlled human dose-ranging result. forum
- Standard pulse charts: ~200–500 mcg SC once daily for 5–10 days. forum
- Extended pulse charts: ~500–670 mcg SC once daily for 10–12 days (higher-intensity immune/stack talk). forum
- Course-total language: Some research-summary pages discuss roughly 1–10 mg total per course with daily splits over ~10 days rather than high daily milligram dosing — another reason not to mix “per day” and “per course” numbers. forum
- Frequency on on-days: Once daily is the default for both oral and subq talk; split dosing is uncommon. forum
- Timing talk: Morning preferred in many charts (oral with meals; subq same clock time); empty-stomach subq is mentioned in some guides but is not backed by controlled timing trials. forum
- Course spacing: Every ~1–6 months is common discussion (often ~3–6 months); some educational charts run a 5-day pulse inside a 4-week cycle, repeated monthly for 2–4 months, then longer rest. Not year-round daily dosing in classic bioregulator lore. forum
- Yearly load (community): Often ~2–4 courses/year rather than open-ended daily injectables. forum
- Oral capsules (consumer bioregulator format): 1–2 capsules daily with meals for ~10–30 days per cycle; originator-style evaluations are often cited as 1 capsule daily for ~20 days. Milligrams of KE per capsule vary by brand and are frequently unlabeled in third-party terms. forumtrial
- Uncertainty / product ID: Vial labeled mg, capsule potency, and actual KE identity are poorly verified without third-party testing; underdose and mislabel are structural research-chem risks. forum
- Animal doses are not human doses: Originator CBA-mouse geroprotection work used ~0.1 μg per animal subcutaneously for five consecutive days each month from 6 months of age until death — nano- to microgram-scale rodent pulses that do not translate 1:1 to human mcg/mg charts. Separate mouse IP comparison work used ~0.01 or 1 μg/kg for several days when comparing Vilon to Thymogen. animal
- Framing: Discussed research / community ranges only — not advice, not prescriptions, not safety-validated protocols. No Western dose-ranging trial establishes a human therapeutic dose. forumtrial
How it may feel
- Days 1–3: No reliable isolated early-effect data. One long-COVID poster described overnight improvement while combining intranasal Vilon and VIP with a large medication, hormone and peptide stack. One regimen description used 250 mcg Vilon twice daily plus 50 mcg VIP twice daily; an earlier passage described 1 mg/day Vilon, so the statements are not merged. Later same-author updates described relapse, a weaker effect and no durable benefit, and credited other interventions more heavily. This cannot assign onset or benefit to Vilon alone. forumanecdote
- Days 4–10 (active pulse window): Community short-course model runs here (often 5–10 consecutive on-days). Most honest logs stay neutral on subjective feel; closest anchors remain preclinical, not human “felt” endpoints. forum
- Days 11–20: End of longer community oral or injectable courses; any delayed immune or recovery claim remains unquantified in controlled human outcome data. forumtrial
- Weeks 2–6 after a pulse: Bioregulator lore expects benefits to lag the dosing window (gene/immune signaling after the peptide is gone). Some users claim delayed “fewer colds” or steadier energy; causality is weak without illness-exposure tracking. anecdoteforum
- Months 1–3 (repeat pulses): Framed as resilience maintenance with 1–4 courses/year, not progressive stacking highs or tolerance ramps like GHS peptides. forum
- No change after 1–2 cycles: Community reassess sleep, illness load, product identity/purity, and whether the goal (infection count vs longevity markers) even matches a short dipeptide pulse — not automatic dose-up. forum
- Multi-year / multi-course: Sparse independent public logs; long-term human KE outcomes poorly characterized outside originator-era summaries. Extract-parent stories do not automatically transfer to research-chem KE. forumtrial
- Success criteria differ by use-case: Longevity biomarker curiosity, fewer seasonal infections, and “stack completionism” use different timelines and different confounds — do not merge them into one expected curve. forum
Cycles people discuss
- Classic bioregulator pulse: Short intensive on-period (most often 5–10 days; some guides 10–12 or 10–20) then weeks-to-months off before the next course. forum
- Monthly mini-pulse scheme: 5 consecutive injection days, then rest for the remainder of a ~4-week cycle; some educational charts repeat monthly for 2–4 cycles (roughly 8–16 weeks of pulsed exposure) then pause. forum
- Seasonal / illness-load pulse: Some users time a course before winter or high-exposure periods rather than fixed calendar longevity cycles. anecdote
- Yearly load: Common discussion is 2–4 courses/year; continuous multi-month daily injectable use is less emphasized than pulsing. forum
- Rotation with other organ bioregulators: Sequence KE with pineal, vascular, cartilage, or CNS cytogens across successive months rather than stacking every organ peptide every day. Example community rotation pattern: Month 1 Vilon (thymus) → Month 2 Epitalon (pineal) → Month 3 Vesugen/Ventfort-class vascular → Month 4 Cartalax → Month 5 brain-class (e.g., Cortagen/Pinealon talk) → repeat. Exact calendars vary widely. forum
- Same-cycle stack vs alternate-month stack: Vilon + Epitalon may run together on the same 5–10 day pulse (separate injection sites) or alternate months; head-to-head human comparisons do not exist. forum
- Stop rules (community logic): Finish the planned short course; reassess after rest rather than escalating mid-pulse for “no feel.” Persistent illness, new autoimmune flares, unexpected clotting-related symptoms, or product contamination concerns are discussed as reasons to stop and re-evaluate. forum
- Why short courses (lore): Originator bioregulator model claims gene-expression nudges persist after the peptide clears, so continuous blood levels are unnecessary — opposite of steady-state drug logic. Whether that model is correct remains unproven independently. trialforum
Timing
- PK reality check: Two-amino-acid peptide — expected to be rapidly proteolyzed to ordinary lysine and glutamic acid; independent modern human ADME package is essentially absent. forumtrial
- Half-life talk: Community and summary pages describe “short / rapid absorption and clearance”; no single agreed independent human t½ number dominates threads. forum
- Why short courses still make sense in the lore: Claimed benefits are framed as lagging chromatin/immune signaling after the pulse ends, not as maintaining plasma KE. anecdoteforum
- Dosing cadence: Once daily oral or subq on on-days is default; no controlled evidence for BID superiority. forum
- Timing preferences: Morning/with meals (oral) or consistent AM subq — practical convention, not PK-optimized from trials. forum
- Route and bioavailability debate: Subq (and sometimes IM) is preferred in research-chem circles for dose control; oral capsules are more convenient and dominate consumer bioregulator brands, but intact dipeptide oral bioavailability is not well documented in independent PK studies. Intranasal appears in some originator-style protocol mentions more than modern US research-chem logs. forumtrial
More on what it is
- Why people search it: Immune-aging and thymus talk, low-side-effect short bioregulator pulses, and longevity stacks next to Epitalon — with far less forum volume than BPC-157 or TB-500. forum
- Oral vs inject lens: Oral capsules dominate consumer bioregulator catalogs; research-chem vials are usually subcutaneous lyophilized powder. Intact oral bioavailability of the free dipeptide is poorly characterized in independent PK work — treat product claims as brand/marketing unless third-party identity testing exists. forumtrial
- Lens for logs: Benefits are framed as delayed gene/immune signaling after short pulses, not day-one stimulation; lifestyle confounders (sleep, illness exposure, other stack members) dominate self-reports. forum
- What it is: Synthetic L-Lys-L-Glu (KE) dipeptide (often listed ~275.3 Da, formula C11H21N3O5) from the Khavinson / St. Petersburg Institute of Bioregulation and Gerontology thymus bioregulator (“cytogen”) line; originally identified as an active sequence motif from thymus-extract work that produced Thymalin. trial
- Mechanism talk (proposed): Cell entry → nuclear/chromatin contact → selective decondensation of facultative heterochromatin and shifts in immune-differentiation / inflammatory gene programs (CD4/CD5, IL-2, NF-κB/CHUK pathway talk); originator reviews also note selective DNA-sequence binding (e.g., TCGA motif cited for KE). Western pharmacology treats nuclear DNA-binding claims as extraordinary and under-replicated outside the originator network. labtrial
- Evidence honesty: Mostly cell culture and rodent work from one research lineage; one often-cited small Russian clinical-era report in elderly diabetes patients (immune + coagulation markers). No large modern Western RCTs, no FDA approval, sold research-use / gray-market only in the US. trial
- Not the same as: Not Thymogen (Glu-Trp / EW — different dipeptide), not Thymalin extract (multi-fraction thymus preparation), not Thymosin Alpha-1 (28-aa immunomodulatory peptide with stronger Western clinical history), not a GH secretagogue, not an FDA anti-aging drug. trial
Stacks
- Classic longevity pair — Vilon + Epitalon (AEDG): Most-discussed combination; narrative is chromatin/gene accessibility (KE) plus pineal/telomerase-framed aging support (Epitalon). Same 5–10 day pulse at separate injection sites, or alternate months. No head-to-head human outcome trial. forum
- Thymus dual — Vilon + Thymalin extract: KE as defined synthetic signal plus multi-fraction thymus extract; some argue complementarity (broad extract + focused chromatin piece), others call it redundant. Attribution of any benefit is muddy. forum
- Triple — Vilon + Epitalon + Thymalin: Popular “immune + pineal + thymic extract” longevity stack in influencer/blog bioregulator content; still research-context only. forum
- Multi-cytomedine / organ rotation: KE sequenced with Pinealon, Cartalax, Ventfort/Vesugen, Crystagen, Cortagen, Chonluten, etc., across months rather than all at once. forum
- Broader immune neighborhood: Sometimes discussed near Thymosin Alpha-1, KPV (mucosal/gut inflammation narratives), or other immune peptides — different mechanisms and evidence bars; do not treat as interchangeable. forum
- Vesugen note: Vesugen (Lys-Glu-Asp) shares the KE motif plus Asp and is framed as vascular rather than pure thymus — sometimes compared or rotated, not identical. forum
- Lifestyle confounders: Sleep, infection exposure, protein/micronutrient basics, and training load often get (deserved) credit for resilience wins that get attributed to the pulse. forum
- Stack ratios: Unlike Wolverine/GLOW pre-mixes, KE is almost always dosed as its own vial/capsule — “ratios” are parallel independent doses, not a fixed blend formula. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Mild redness, itch, tenderness, or brief local irritation are the most commonly discussed practical downsides with subq use — usually transient and not peptide-specific. forum
- Systemic AE signal (published work): Originator-era and secondary summaries describe Vilon as well tolerated with rare/mild systemic effects; no consistent headache, nausea, fatigue, or hormonal AE table is established in controlled literature. Sparse reporting ≠ comprehensive long-term safety proof. trialforum
- Cancer / gene-regulation caution: Proposed chromatin and oncogene-expression effects (including originator reports of reduced HER-2/neu expression in transgenic mouse mammary models with KE/Epitalon) cut both ways: anti-tumor rodent signals exist, but gene-regulatory immunomodulators are still discussed cautiously in active malignancy or high hereditary cancer risk. Not a cancer treatment. animalforum
- Pregnancy / lactation / under-18: No meaningful safety dataset — commonly listed as avoid in research-chem caution lists. forum
- Gray-market / product risk: Mislabel, underdose, wrong peptide, endotoxin/contamination, and non-sterile injectables are structural research-chem risks and often exceed pharmacologic side-effect risk for this dipeptide. forum
- Extract ≠ synthetic: Thymalin or Thymogen clinical-era stories do not automatically transfer to research KE sold online. forumtrial
- Oral product opacity: Capsule milligram claims and actual KE content vary; absence of third-party COAs is common. forum
- Low chatter ≠ safe: Short courses, limited monitoring, and niche user base mean missing side-effect reports are not long-term proof. forum
- Animal chronic use: Long-term mouse administration in lifespan studies was reported without unfavorable developmental effects in originator writeups; rodent safety does not equal human clearance. animal
- Autoimmune / immune-modulation caution: Immune-mod framing leads communities to urge extra caution in active autoimmunity or uncontrolled inflammatory disease — theoretical, not a quantified adverse-event rate table. forum
- Coagulation flag: The 2007 diabetes/age cohort reported coagulation-hemostasis parameter shifts — anyone on anticoagulants/antiplatelets, with clotting disorders, or facing surgery should treat that as a specific discussion point, not a footnote. trial
- Human safety data thin: Class described as well-tolerated in originator work; independent Western pharmacovigilance essentially absent. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.